/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
With a market cap of $20.9 billion, Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. It markets a diverse portfolio of oncology, immunology, and dermatology medicines, including JAKAFI, OPZELURA, and ICLUSIG.
The Wilmington, Delaware-based company is set to unveil its fiscal Q4 2025 results soon. Ahead of this event, analysts expect INCY to report a profit of $1.66 per share, up 52.3% from $1.09 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.
